<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK143129" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK143129/" /><meta name="ncbi_pagename" content="Familial Porphyria Cutanea Tarda - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Familial Porphyria Cutanea Tarda - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Familial Porphyria Cutanea Tarda" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/09/08" /><meta name="citation_author" content="Lawrence U Liu" /><meta name="citation_author" content="John Phillips" /><meta name="citation_author" content="Herbert Bonkovsky" /><meta name="citation_author" content="Porphyrias Consortium of the Rare Diseases Clinical Research Network" /><meta name="citation_pmid" content="23741761" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK143129/" /><meta name="citation_keywords" content="Familial PCT" /><meta name="citation_keywords" content="F-PCT" /><meta name="citation_keywords" content="Porphyria Cutanea Tarda, Type II" /><meta name="citation_keywords" content="Type II PCT" /><meta name="citation_keywords" content="Familial PCT" /><meta name="citation_keywords" content="F-PCT" /><meta name="citation_keywords" content="Type II PCT" /><meta name="citation_keywords" content="Porphyria Cutanea Tarda, Type II" /><meta name="citation_keywords" content="Uroporphyrinogen decarboxylase" /><meta name="citation_keywords" content="UROD" /><meta name="citation_keywords" content="Familial Porphyria Cutanea Tarda" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Familial Porphyria Cutanea Tarda" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Lawrence U Liu" /><meta name="DC.Contributor" content="John Phillips" /><meta name="DC.Contributor" content="Herbert Bonkovsky" /><meta name="DC.Contributor" content="Porphyrias Consortium of the Rare Diseases Clinical Research Network" /><meta name="DC.Date" content="2016/09/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK143129/" /><meta name="description" content="Familial porphyria cutanea tarda (F-PCT) is characterized by: skin findings including blistering over the dorsal aspects of the hands and other sun-exposed areas of skin, skin friability after minor trauma, facial hypertrichosis and hyperpigmentation, and severe thickening of affected skin areas (pseudoscleroderma); and an increased risk for hepatocellular carcinoma (HCC)." /><meta name="og:title" content="Familial Porphyria Cutanea Tarda" /><meta name="og:type" content="book" /><meta name="og:description" content="Familial porphyria cutanea tarda (F-PCT) is characterized by: skin findings including blistering over the dorsal aspects of the hands and other sun-exposed areas of skin, skin friability after minor trauma, facial hypertrichosis and hyperpigmentation, and severe thickening of affected skin areas (pseudoscleroderma); and an increased risk for hepatocellular carcinoma (HCC)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK143129/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/porphyria-ct/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK143129/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C9E6FE03FBE0100000000081702F1.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK143129_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK143129_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pnknd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fa/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK143129_"><span class="title" itemprop="name">Familial Porphyria Cutanea Tarda</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Familial PCT; F-PCT; Porphyria Cutanea Tarda, Type II; Type II PCT</div><p class="contrib-group"><span itemprop="author">Lawrence U Liu</span>, MD, <span itemprop="author">John Phillips</span>, PhD, <span itemprop="author">Herbert Bonkovsky</span>, MD; <span itemprop="author">Porphyrias Consortium of the Rare Diseases Clinical Research Network</span>.</p><a data-jig="ncbitoggler" href="#__NBK143129_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK143129_ai__"><div class="contrib half_rhythm"><span itemprop="author">Lawrence U Liu</span>, MD<div class="affiliation small">Icahn School of Medicine at Mount Sinai<br />New York, New York<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.ianistnuom@uil.ecnerwal" class="oemail">gro.ianistnuom@uil.ecnerwal</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John Phillips</span>, PhD<div class="affiliation small">University of Utah School of Medicine<br />Salt Lake City, Utah<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.hatu.csh@spillihp.nhoj" class="oemail">ude.hatu.csh@spillihp.nhoj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Herbert Bonkovsky</span>, MD<div class="affiliation small">Carolinas Medical Center<br />Charlotte, North Carolina<br />University of North Carolina at Chapel Hill<br />Chapel Hill, North Carolina<br />University of Connecticut<br />Farmington, Connecticut<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.sanilorac@yksvoknob.trebreh" class="oemail">gro.sanilorac@yksvoknob.trebreh</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Porphyrias Consortium of the Rare Diseases Clinical Research Network</span></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 6, 2013</span>; Last Update: <span itemprop="dateModified">September 8, 2016</span>.</p><p><em>Estimated reading time: 19 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="porphyria-ct.Summary" itemprop="description"><h2 id="_porphyria-ct_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Familial porphyria cutanea tarda (F-PCT) is characterized by: skin findings including blistering over the dorsal aspects of the hands and other sun-exposed areas of skin, skin friability after minor trauma, facial hypertrichosis and hyperpigmentation, and severe thickening of affected skin areas (pseudoscleroderma); and an increased risk for hepatocellular carcinoma (HCC).</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of F-PCT is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of elevated porphyrins in the urine (predominantly uroporphyrin and heptacarboxylporphyrin) and confirmed by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Reduction of body iron stores and liver iron content preferably by phlebotomy;low-dose antimalarial agents (chloroquine or hydroxychloroquine); eliminate known susceptibility factors including excess hepatic iron, alcohol consumption, smoking, oral estrogens, and hepatotoxins. In persons with end-stage renal disease, erythropoietin therapy has been shown to correct anemia, mobilize iron, and support phlebotomy. Iron chelation therapy (e.g., deferasirox, deferiprone, or desferrioxamine) may be considered if phlebotomy is contraindicated.</p><p><i>Prevention of primary manifestations:</i> Identification and avoidance of susceptibility factors (where applicable); protection from sunlight in the symptomatic phase; vaccination against hepatitis A and B.</p><p><i>Surveillance:</i> Monitor urinary porphyrin levels annuall; resume phlebotomies when levels begin to rise. Monitor annually for diabetes mellitus with fasting glucose. Monitor for HCC annually with serum AFP concentration and hepatic ultrasonography; monitor every six months in those with advanced chronic hepatitis C and/or alcoholic cirrhosis.</p><p><i>Agents/circumstances to avoid:</i> Susceptibility factors (e.g., iron supplements, alcohol consumption, smoking, oral estrogen, and hepatotoxins); exposure to sunlight in symptomatic phase.</p><p><i>Evaluation of relatives at risk:</i> If the family-specific <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known, clarify the genetic status of at-risk relatives so that those with a <i>UROD</i> pathogenic variant can avoid known susceptibility factors.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>F-PCT is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. At least one parent of most individuals with F-PCT has a <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; however, few individuals diagnosed with F-PCT have a clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent because <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is significantly reduced. Each child of an individual with F-PCT has a 50% chance of inheriting the pathogenic variant. Because of reduced penetrance, the likelihood of the offspring developing clinical manifestations of F-PCT is small. Prenatal diagnosis for a pregnancy at increased risk is possible if the pathogenic variant in an affected family member is known. Because of reduced penetrance, results of prenatal testing are not useful in accurately predicting whether or not an individual with one <i>UROD</i> pathogenic variant will develop F-PCT or if so, the age of onset or specific symptoms.</p></div></div><div id="porphyria-ct.Diagnosis"><h2 id="_porphyria-ct_Diagnosis_">Diagnosis</h2><div id="porphyria-ct.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Familial porphyria cutanea tarda (F-PCT) <b>should be suspected</b> in individuals with the following clinical and biochemical features.</p><p><b>Clinical features</b> (typically developing in the 4th-5th decade):</p><ul><li class="half_rhythm"><div>Photosensitivity resulting in fluid-filled vesicles developing over the dorsal aspects of the hands and other sun-exposed areas of skin (e.g., forearms, face and scalp, ears, neck, legs, and feet)</div></li><li class="half_rhythm"><div>Skin fragility after minor trauma (which may occur over the same areas where the blisters develop)</div></li><li class="half_rhythm"><div>Facial hypertrichosis and hyperpigmentation</div></li><li class="half_rhythm"><div>Severe thickening of the affected skin areas (pseudoscleroderma) that resembles systemic scleroderma</div></li></ul><p><b>Biochemical features</b> (see <a class="figpopup" href="/books/NBK143129/table/porphyria-ct.T.biochemical_features_of_f/?report=objectonly" target="object" rid-figpopup="figporphyriactTbiochemicalfeaturesoff" rid-ob="figobporphyriactTbiochemicalfeaturesoff">Table 1</a>):</p><ul><li class="half_rhythm"><div class="half_rhythm">Hepatic uroporphyrinogen decarboxylase enzyme activity is less than approximately 20% of normal. The amount of protein remains at approximately 50%.</div></li><li class="half_rhythm"><div class="half_rhythm">Plasma porphyrins are incresed.</div><div class="half_rhythm">Note: Levels are higher in persons with F-PCT with renal failure.</div></li><li class="half_rhythm"><div class="half_rhythm">Urine porphyrins are elevated. Predominance of uroporphyrin and heptacarboxylporphyrin; hexa- and pentacarboxylporphyrins and coproporphyrin levels are also increased.</div><div class="half_rhythm">Note: Isomer analysis of the uroporphyrin shows a significant increase in isomer I uroporphyrin.</div></li><li class="half_rhythm"><div class="half_rhythm">Stool heptacarboxylporphyrin, isocoproporphyrin, and pentaporphyrins are increased.</div></li><li class="half_rhythm"><div class="half_rhythm">Urine delta-aminolevulinic acid (ALA) is normal or minimally increased.</div></li><li class="half_rhythm"><div class="half_rhythm">Porphobilinogen (PBG) levels are normal.</div></li><li class="half_rhythm"><div class="half_rhythm">In persons with severe F-PCT, urine may appear pink in color and fluoresces bright pink when excited by long UV-blue light.</div></li></ul><div id="porphyria-ct.T.biochemical_features_of_f" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Biochemical Features of Familial Porphyria Cutanea Tarda</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK143129/table/porphyria-ct.T.biochemical_features_of_f/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-ct.T.biochemical_features_of_f_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Biochemical Finding</th></tr></thead><tbody><tr><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Deficient enzyme</b></td><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatic uroporphyrinogen decarboxylase</td></tr><tr><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Enzyme activity</b></td><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c; ~20% of normal</td></tr><tr><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Plasma</b></td><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; Uroporphyrin, heptacarboxylporphyrin (~620 nm)&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Urine</b></td><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; Uroporphyrin, heptacarboxylporphyrin</td></tr><tr><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Stool</b></td><td headers="hd_h_porphyria-ct.T.biochemical_features_of_f_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; Heptacarboxylporphyrin, isocoproporphyrins + pentaporphyrins</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="porphyria-ct.TF.1.1"><p class="no_margin">Fluorescence emission peak of diluted plasma at neutral pH, following excitation at 400-410 nm</p></div></dd></dl></div></div></div></div><div id="porphyria-ct.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of F-PCT <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with elevated porphyrins in the urine (predominantly uroporphyrin and heptacarboxylporphyrin, and identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>UROD</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK143129/table/porphyria-ct.T.molecular_genetic_testing/?report=objectonly" target="object" rid-figpopup="figporphyriactTmoleculargenetictesting" rid-ob="figobporphyriactTmoleculargenetictesting">Table 2</a>).</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>UROD</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>UROD</i> and other genes of interest (see <a href="#porphyria-ct.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>UROD</i>) fails to confirm a diagnosis in an individual with features of F-PCT. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="porphyria-ct.T.molecular_genetic_testing" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Familial Porphyria Cutanea Tarda</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK143129/table/porphyria-ct.T.molecular_genetic_testing/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-ct.T.molecular_genetic_testing_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_porphyria-ct.T.molecular_genetic_testing_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_porphyria-ct.T.molecular_genetic_testing_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_porphyria-ct.T.molecular_genetic_testing_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_porphyria-ct.T.molecular_genetic_testing_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>UROD</i></td><td headers="hd_h_porphyria-ct.T.molecular_genetic_testing_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_porphyria-ct.T.molecular_genetic_testing_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_porphyria-ct.T.molecular_genetic_testing_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_porphyria-ct.T.molecular_genetic_testing_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="porphyria-ct.TF.2.1"><p class="no_margin">See <a href="/books/NBK143129/#porphyria-ct.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="porphyria-ct.TF.2.2"><p class="no_margin">See <a href="#porphyria-ct.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="porphyria-ct.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="porphyria-ct.TF.2.4"><p class="no_margin"><a href="http://www.rarediseasesnetwork.org/cms/porphyrias/7201" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rare Disease Clinical Research Network Porphyrias Consortium ongoing study</a></p></div></dd><dt>5. </dt><dd><div id="porphyria-ct.TF.2.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="porphyria-ct.TF.2.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd></dl></div></div></div></div></div><div id="porphyria-ct.Clinical_Characteristics"><h2 id="_porphyria-ct_Clinical_Characteristics_">Clinical Characteristics</h2><div id="porphyria-ct.Clinical_Description"><h3>Clinical Description</h3><p>Most individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> porphyria cutanea tarda (F-PCT) develop skin changes in the fourth or fifth decade of life. Disease manifestations are more common in men than women.</p><p><b>Skin</b> findings include photosensitivity resulting in the formation of blisters over the dorsal aspects of the hands and other sun-exposed areas of skin (e.g., forearms, face and scalp, ears, neck, legs, and feet), skin friability after minor trauma which can occur over the same areas where the blisters develop, facial hypertrichosis and hyperpigmentation, and severe thickening of the affected skin areas (pseudoscleroderma) that resembles systemic scleroderma.</p><p>Histopathology of the blisters in F-PCT demonstrates subepidermal blistering; deposition of PAS-positive material around blood vessels and fine fibrillar material in the upper dermis and at the dermoepithelial junction; and splits in the lamina lucida of the basement membrane [<a class="bk_pop" href="#porphyria-ct.REF.dabski.1991.28">Dabski &#x00026; Beutner 1991</a>]. These findings are not diagnostic of F-PCT and can be found in other cutaneous porphyrias and pseudoporphyria.</p><p><b>Hepatocellular carcinoma.</b> The risk for hepatocellular carcinoma is increased in individuals with F-PCT, especially in those with other risk factors predisposing to advanced liver disease (e.g., hepatitis C, alcoholic liver disease) [<a class="bk_pop" href="#porphyria-ct.REF.gisbert.2004.689">Gisbert et al 2004</a>, <a class="bk_pop" href="#porphyria-ct.REF.rossmannringdahl.2005.337">Rossmann-Ringdahl &#x00026; Olsson 2005</a>, <a class="bk_pop" href="#porphyria-ct.REF.cassiman.2008.237">Cassiman et al 2008</a>].</p></div><div id="porphyria-ct.Susceptibility_Factors"><h3>Susceptibility Factors</h3><p>Several inherited, environmental, and infectious factors are known or suspected to play an important role in the development of manifestations of F-PCT; heterozygosity for a <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> alone does not account for the clinical manifestations of F-PCT.</p><ul><li class="half_rhythm"><div><b><i>HFE</i> pathogenic variants</b> that lead to increased intestinal iron absorption increase the risk of developing F-PCT.</div></li><li class="half_rhythm"><div><b>Iron overload.</b> Mild to moderate iron overload is common in individuals with F-PCT. Some degree of hepatic siderosis is seen in almost all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. Conversely, iron deficiency has been found to be protective.</div></li><li class="half_rhythm"><div><b>Alcohol.</b> PCT has long been associated with excessive alcohol use.</div></li><li class="half_rhythm"><div><b>Smoking and cytochrome P450 enzymes.</b> Smoking is commonly associated with alcohol use in PCT [<a class="bk_pop" href="#porphyria-ct.REF.egger.2002.419">Egger et al 2002</a>].</div></li><li class="half_rhythm"><div><b>Estrogens.</b> Estrogen use is common in women with PCT [<a class="bk_pop" href="#porphyria-ct.REF.grossman.1979.277">Grossman et al 1979</a>, <a class="bk_pop" href="#porphyria-ct.REF.sixeldietrich.1985.13">Sixel-Dietrich &#x00026; Doss 1985</a>, <a class="bk_pop" href="#porphyria-ct.REF.egger.2002.419">Egger et al 2002</a>].</div></li><li class="half_rhythm"><div><b>Estrogen mimetics/antagonists</b> (e.g., tamoxifen)</div></li><li class="half_rhythm"><div><b>Toxins.</b> PCT has been described in those exposed to hexachlorobenzene, and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin), chemicals that were subsequently shown to cause hepatic UROD deficiency and biochemical features resembling PCT in laboratory animals. The compounds are potent inducers of the cytochrome P450 enzymes, including hepatic CYP1A2.</div></li><li class="half_rhythm"><div><b>Antioxidants.</b> Substantial reductions in plasma levels of ascorbate and carotenoids have been noted in some individuals with PCT [<a class="bk_pop" href="#porphyria-ct.REF.sinclair.1997.197">Sinclair et al 1997</a>, <a class="bk_pop" href="#porphyria-ct.REF.rocchi.1999.861">Rocchi et al 1999</a>].</div></li><li class="half_rhythm"><div><b>End-stage renal disease (ESRD)</b> can lead to the development of F-PCT for reasons still not fully understood. The manifestations of F-PCT in persons with ESRD are usually more severe and sometimes include severe cutaneous mutilation. Lack of urinary porphyrin excretion in these individuals leads to much higher concentrations of porphyrins in plasma; these excess porphyrins are poorly dialyzable [<a class="bk_pop" href="#porphyria-ct.REF.anderson.1990.315">Anderson et al 1990</a>].</div></li><li class="half_rhythm"><div><b>Hepatitis C.</b> Reported prevalence of hepatitis C in individuals with PCT has ranged from 21% to 92% in various countries [<a class="bk_pop" href="#porphyria-ct.REF.ryan_caballes.2012.880">Ryan Caballes et al 2012</a>]; it is seen more frequently in type I PCT (<a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a>) than in F-PCT [<a class="bk_pop" href="#porphyria-ct.REF.mu_ozsantos.2010.69">Mu&#x000f1;oz-Santos et al 2010</a>].</div></li><li class="half_rhythm"><div><b>Human immunodeficiency virus (HIV).</b> PCT is associated with HIV infection, although less commonly than with hepatitis C infection [<a class="bk_pop" href="#porphyria-ct.REF.wissel.1987.107">Wissel et al 1987</a>].</div></li></ul></div><div id="porphyria-ct.Pathophysiology"><h3>Pathophysiology</h3><p>Hepatic UROD deficiency develops in the presence of multiple <a href="#porphyria-ct.Susceptibility_Factors">susceptibility factors</a> that are believed to contribute to the generation of a UROD enzyme inhibitor. When hepatic UROD is significantly inhibited, oxidized porphyrins (mostly uroporphyrin and heptacarboxylporphyrin) accumulate in the liver and are then transported out of hepatocytes into the plasma and eventually into the urine. These excess porphyrins are deposited in the skin and other tissues.</p></div><div id="porphyria-ct.GenotypePhenotype_Correlati"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> are known for F-PCT.</p></div><div id="porphyria-ct.Nomenclature"><h3>Nomenclature</h3><p>The term, type III PCT, has been used to refer to <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> PCT (i.e., &#x0003e;1 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member) not associated with mutation of <i>UROD</i>. There are very few well-documented reports; some of the data on the so-called type III PCT result from studies in which UROD activity has been used to diagnose individuals with type III when they in fact have F-PCT.</p></div><div id="porphyria-ct.Penetrance"><h3>Penetrance</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of F-PCT is low. Usually individuals with F-PCT are <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family). No population-based studies have been done to determine the frequency of pathogenic variants in <i>UROD</i> in asymptomatic individuals to provide an estimate of penetrance.</p><p><a class="bk_pop" href="#porphyria-ct.REF.cantatorefrancis.2010.529">Cantatore-Francis et al [2010]</a> described a family in which three <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> members (<a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and 2 sibs) had <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> <i>UROD</i> pathogenic variants and four unaffected members (father, mother, and 2 sibs) had a heterozygous <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The multiple and varied clinical findings of the proband age seven years and the affected sibs ages 11 years and ten years are described in detail [<a class="bk_pop" href="#porphyria-ct.REF.cantatorefrancis.2010.529">Cantatore-Francis et al 2010</a>].</p></div><div id="porphyria-ct.Prevalence"><h3>Prevalence</h3><p>PCT is the most common type of porphyria. The proportion of F-PCT ranges from 15% to 50% of all PCT, depending on the frequency of the susceptibility factors and founder effects [<a class="bk_pop" href="#porphyria-ct.REF.aarsand.2009.795">Aarsand et al 2009</a>].</p><p>Its prevalence has been estimated to range from 5:100,000 to 10:100,000, with a higher prevalence reported in certain European populations [<a class="bk_pop" href="#porphyria-ct.REF.christiansen.2005.227">Christiansen et al 2005</a>, <a class="bk_pop" href="#porphyria-ct.REF.pobleteguti_rrez.2004.372">Poblete-Guti&#x000e9;rrez et al 2004</a>, <a class="bk_pop" href="#porphyria-ct.REF.badenas.2009.346">Badenas et al 2009</a>].</p></div></div><div id="porphyria-ct.Genetically_Related_Allelic"><h2 id="_porphyria-ct_Genetically_Related_Allelic_">Genetically Related (Allelic) Disorders</h2><p>Biallelic pathogenic variants in <i>UROD</i> cause <a href="/books/n/gene/hep/">hepatoerythropoietic porphyria</a> (HEP) (see also <a href="#porphyria-ct.Differential_Diagnosis">Differential Diagnosis</a>). With few exceptions, the <i>UROD</i> pathogenic variants identified in HEP have not been found in F-PCT. In HEP, at least one of the mutated <i>UROD</i> alleles must preserve some degree of catalytic activity.</p></div><div id="porphyria-ct.Differential_Diagnosis"><h2 id="_porphyria-ct_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Type I PCT (<a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a>; no <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</b> Sporadic porphyria cutanea tarda (PCT) is highly influenced by <a href="#porphyria-ct.Susceptibility_Factors">susceptibility factors associated with PCT</a>; often several are present in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, including mutation of <i>HFE</i>. Sporadic PCT is clinically indistinguishable from <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> PCT.</p><p><b>African iron overload</b> (OMIM <a href="http://omim.org/entry/601195" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601195</a>) results from a predisposition to iron overload that is exacerbated by excessive intake of dietary iron. It is particularly prevalent among Africans who drink a traditional beer brewed in non-galvanized steel drums. Mutation of other yet-to-be-defined iron-related genes predisposes to this condition. A specific <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (p.Gln248His) in <i>SLC40A1</i> (<a href="/nuccore/NM_014585.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_014585.5</a>) encoding ferroportin has been associated with a tendency to iron overload in Africans and African Americans [<a href="/books/NBK1440/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">McNamara et al 2005</a>, <a href="/books/NBK1440/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rivers et al 2007</a>]. Another probable pathogenic variant (p.Asp270Val) in <i>SLC40A1</i> was discovered in an African American man with mild iron overload [<a href="/books/NBK1440/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Lee et al 2012</a>].</p><p><a href="/books/n/gene/porphyria-var/"><b>Variegate porphyria</b></a>
<b>(VP)</b> and <a href="/books/n/gene/hcp/"><b>hereditary coproporphyria</b></a>
<b>(HCP).</b> Blistering skin lesions in VP and HCP are nearly identical to those in PCT, with the lesions being more common in VP than in HCP. In contrast, HCP is generally accompanied by neurovisceral features, especially bouts of severe abdominal pain, which are not observed in PCT.</p><p><a href="/books/n/gene/cep/"><b>Congenital erythropoietic porphyria</b></a>
<b>(CEP)</b> and <a href="/books/n/gene/hep/"><b>hepatoerythropoietic porphyria</b></a>
<b>(HEP).</b> Although the skin lesions of CEP and HEP resemble those of PCT, they are usually more severe and mutilating. Also in CEP and HEP the skin lesions appear early in life (e.g., infancy and childhood), whereas in PCT the lesions generally appear during the fourth and fifth decades of life.</p><p>In both CEP and HEP the increased severity is attributed to the plasma concentration of porphyrin. <a class="bk_pop" href="#porphyria-ct.REF.mehrany.2004.205">Mehrany et al [2004]</a> described a child age four years with PCT who was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>HFE</i> p.Cys282Tyr <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p>CEP can be mistaken for HEP or PCT; however, urine porphyrin analysis (demonstrating uroporphyrin and coproporphyrin type I) rules out these other types of cutaneous porphyria. Fecal analysis may be necessary in individuals with later onset.</p><p><b>Pseudoporphyria.</b> Although the skin histopathologic findings of pseudoporphyria are indistinguishable from those of PCT, pseudoporphyria does not cause porphyrin biochemical abnormalities. Drugs are implicated in the appearance of this condition [<a class="bk_pop" href="#porphyria-ct.REF.barzilay.2001.195">Barzilay et al 2001</a>].</p></div><div id="porphyria-ct.Management"><h2 id="_porphyria-ct_Management_">Management</h2><div id="porphyria-ct.Evaluations_Following_Initi"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> porphyria cutanea tarda (F-PCT), the following evaluations and/or testing for all known susceptibility factors are recommended:</p><ul><li class="half_rhythm"><div>Medical history regarding alcohol consumption, tobacco exposure, medication use (estrogens), exposure to hepatotoxins (e.g., hexachlorobenzene)</div></li><li class="half_rhythm"><div>Evaluation for excess hepatic iron</div></li><li class="half_rhythm"><div>Targeted analysis for <i>HFE</i> pathogenic variants (see <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-related familial hemochromatosis</a>)</div></li><li class="half_rhythm"><div>Evaluation for hepatitis C and/or human immunodeficiency virus infection</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="porphyria-ct.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment is highly effective; it should only be initiated after the diagnosis is well established. The mainstays of therapy for PCT are reduction of body iron stores and liver iron content and use of low-dose antimalarial agents (chloroquine or hydroxychloroquine).</p><p><b>Iron reduction.</b> In most centers serial phlebotomy is the preferred mode of reducing body iron stores and liver iron content. Iron chelation therapy (e.g., deferasirox, deferiprone, or desferrioxamine) is less efficient and more costly than therapeutic phlebotomies in reducing iron, but may be considered if the latter is contraindicated [<a class="bk_pop" href="#porphyria-ct.REF.rocchi.1987.393">Rocchi et al 1987</a>].</p><p>Serum ferritin concentration should be measured before starting phlebotomy treatment. Typically, approximately 450 mL of blood is removed during a therapeutic phlebotomy, usually initially at two-week intervals. Hemoglobin levels (which are generally &#x0003e;10-11 g/dL) are followed as safety (not therapeutic) targets to prevent symptomatic anemia. The therapeutic target is to reduce the serum ferritin concentration to the low-normal range (15-25 ng/mL), which is associated with tissue iron depletion but usually not anemia.</p><p>Phlebotomy treatment is also guided by plasma (or serum) porphyrin levels, which are more convenient to measure repeatedly than urine porphyrins, and which decrease more slowly than the serum ferritin concentration. Plasma porphyrin levels usually decline from initial concentrations of 10-25 &#x003bc;g/dL to below the upper limit of normal (~1 &#x003bc;g/dL) within weeks after phlebotomies are completed [<a class="bk_pop" href="#porphyria-ct.REF.rocchi.1986.36">Rocchi et al 1986</a>, <a class="bk_pop" href="#porphyria-ct.REF.ratnaike.1988.3">Ratnaike et al 1988</a>].</p><p>Development of new skin lesions generally ceases as plasma porphyrin levels become normal; however, therapy should be continued until the serum ferritin concentration has reached the low end of normal. The chronic skin lesions of PCT are slow to resolve, and some chronic scarring may remain indefinitely.</p><p>After a remission has been achieved, continued phlebotomies are generally not needed unless initial evaluation has determined the presence of <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-related familial hemochromatosis</a>. For persons with the <i>HFE</i> genotypes p.Cys282Tyr / p.Cys282Tyr or p.Cys282Tyr / p.His63Asp, management guidelines for <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-related familial hemochromatosis</a> should be followed.</p><p>Although not essential, adherence to a low-iron diet, especially with restriction of intake of red meat and liver (rich sources of heme iron, which is absorbed better than iron from vegetable sources) is reasonable, especially in those with <i>HFE</i> pathogenic variants. In addition, the ingestion of tea with lunch or dinner further reduces the gastrointestinal absorption of iron.</p><p>Note: Treatment of PCT in persons with end-stage renal disease is more difficult since the option for phlebotomy is often limited by anemia. However, in several instances erythropoietin therapy has been shown to correct anemia, mobilize iron, and support phlebotomy [<a class="bk_pop" href="#porphyria-ct.REF.shieh.2000.645">Shieh et al 2000</a>]. Such individuals may also be considered for iron chelation therapy.</p><p><b>Low-dose antimalarial agents.</b> A low-dose regimen of twice-weekly hydroxychloroquine (100 mg) or chloroquine (125 mg) is also effective and most appropriate when phlebotomy is contraindicated or poorly tolerated [<a class="bk_pop" href="#porphyria-ct.REF.bruce.1998.810">Bruce &#x00026; Ahmed 1998</a>]. Note: Chloroquine is not recommended in persons with increased serum ferritin concentration [<a class="bk_pop" href="#porphyria-ct.REF.st_lzel.2003.309">St&#x000f6;lzel et al 2003</a>].</p><p>Although the use of low-dose antimalarial agents is preferred at many centers because they are less costly and more convenient, these agents do not deplete hepatic iron and the mechanism of their action in the treatment of PCT is not fully understood. Combining both treatment modalities (i.e., antimalarial agent therapy and phlebotomy) may be beneficial if the individual is unable to tolerate full courses of phlebotomy.</p><p><b>Other.</b> Individuals are advised to stop drinking alcohol and smoking and to discontinue further oral estrogen use.</p><p>Adequate intake of ascorbic acid and other nutrients may be recommended although this is not considered to be primary therapy.</p><p>PCT may also improve after treatment of coexisting hepatitis C. PCT should be treated first in most individuals:</p><ul><li class="half_rhythm"><div>PCT generally causes more symptoms and can be treated more quickly and effectively than hepatitis C.</div></li><li class="half_rhythm"><div>Some evidence shows that hepatitis C treatment may be more effective after iron reduction [<a class="bk_pop" href="#porphyria-ct.REF.desai.2012.41">Desai et al 2012</a>, <a class="bk_pop" href="#porphyria-ct.REF.ryan_caballes.2012.880">Ryan Caballes et al 2012</a>].</div></li><li class="half_rhythm"><div>Both interferon and ribavirin (used in the treatment of hepatitis C) commonly cause anemia, which usually precludes phlebotomy for PCT.</div></li></ul><p>Attainment and maintenance of an iron-reduced state decreases the severity and progression of chronic hepatitis C and probably also reduces the risk of developing hepatocellular carcinoma [<a class="bk_pop" href="#porphyria-ct.REF.ryan_caballes.2012.880">Ryan Caballes et al 2012</a>].</p></div><div id="porphyria-ct.Prevention_of_Primary_Manif"><h3>Prevention of Primary Manifestations</h3><p>Identification and avoidance of susceptibility factors (where applicable) is advised. See <a href="#porphyria-ct.AgentsCircumstances_to_Avoi">Agents/Circumstances to Avoid</a>.</p><p>Vaccination against hepatitis A and B is appropriate.</p></div><div id="porphyria-ct.Surveillance"><h3>Surveillance</h3><p>It is advisable to follow porphyrin levels annually and resume phlebotomies (see <a href="#porphyria-ct.Treatment_of_Manifestations">Treatment of Manifestations</a>) if porphyrin levels begin to rise in the presence of cutaneous signs. Note: Increase in urinary total porphyrins may also be caused by an increase in coproporphyrin (which is of no relevance with regard to the PCT); thus, when levels are only moderately increased, urinary porphyrin fractionation should be performed.</p><p>Because of reports of an association between diabetes mellitus and PCT [<a class="bk_pop" href="#porphyria-ct.REF.mu_ozsantos.2011.486">Mu&#x000f1;oz-Santos et al 2011</a>], annual screening with a fasting glucose level is recommended, particularly in those with hypertension (BP &#x0003e;135/80 mm Hg).</p><p>Hepatocellular cancer (HCC) surveillance relies on a combination of serum AFP determinations and hepatic ultrasonography. No guidelines as to the frequency of these tests are currently available due to the rarity of PCT and even rarer occurrence of HCC. Surveillance is usually performed annually; however, in those with advanced chronic hepatitis C and/or alcoholic cirrhosis, hepatologists generally agree that surveillance for HCC should be at least every six months.</p></div><div id="porphyria-ct.AgentsCircumstances_to_Avoi"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Susceptibility factors (if known) (e.g., iron supplements, alcohol consumption, smoking, oral estrogen use, and hepatotoxins such as hexachlorobenzene)</div></li><li class="half_rhythm"><div>Exposure to sunlight in symptomatic phase</div></li></ul></div><div id="porphyria-ct.Evaluation_of_Relatives_at"><h3>Evaluation of Relatives at Risk</h3><p>Testing at-risk relatives of an individual with F-PCT to identify those with a <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not expected to alter their management due to the low risk of development of the signs and symptoms of PCT. Nevertheless, if the family-specific <i>UROD</i> pathogenic variant is known, it is reasonable to clarify the genetic status of at-risk relatives so that those with a <i>UROD</i> pathogenic variant can avoid known susceptibility factors.</p><p>See <a href="#porphyria-ct.Related_Genetic_Counseling">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="porphyria-ct.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Pregnancy is generally not complicated by F-PCT. Women with active F-PCT should be able to carry pregnancies to term [<a class="bk_pop" href="#porphyria-ct.REF.aziz_ibrahim.2004.574">Aziz Ibrahim &#x00026; Esen 2004</a>, <a class="bk_pop" href="#porphyria-ct.REF.toll_nes.2011.217">Toll&#x000e5;nes et al 2011</a>].</p><p>It is recommended that women with F-PCT be treated prior to the onset of planned pregnancies.</p></div><div id="porphyria-ct.Therapies_Under_Investigati"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="porphyria-ct.Genetic_Counseling"><h2 id="_porphyria-ct_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="porphyria-ct.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Familial porphyria cutanea tarda (F-PCT) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>.</p></div><div id="porphyria-ct.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Most individuals diagnosed with F-PCT inherited a <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from a parent. However, few individuals diagnosed with F-PCT have a clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent because <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> is significantly reduced.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with F-PCT may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; the proportion of cases caused by a <i>de novo</i> pathogenic variant is unknown.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Evaluation of parents may determine that an asymptomatic parent has a <i>UROD</i> pathogenic variant. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed on the parents of the proband.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband&#x02019;s parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the pathogenic variant is 50%. Because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, the likelihood of the sib developing F-PCT is small.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with F-PCT has a 50% chance of inheriting the <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, the likelihood of offspring developing F-PCT is small.</p><p><b>Other family members</b></p><ul><li class="half_rhythm"><div>The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents.</div></li><li class="half_rhythm"><div>If a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</div></li></ul></div><div id="porphyria-ct.Related_Genetic_Counseling"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#porphyria-ct.Evaluation_of_Relatives_at">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with type II PCT has a <i>UROD</i> pathogenic variant, the <i>UROD</i> pathogenic variant is likely <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults with type II PCT.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="porphyria-ct.Prenatal_Testing_and_Preimp"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>UROD</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="porphyria-ct.Resources"><h2 id="_porphyria-ct_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>British Porphyria Association</b></div><div>United Kingdom</div><div><b>Phone:</b> 0300 30 200 30</div><div><b>Email:</b> helpline@porphyria.org.uk</div><div><a href="http://www.porphyria.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyria.org.uk</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=porphyriacutaneatarda" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria cutanea tarda</a></div></li><li class="half_rhythm"><div><b>American Porphyria Foundation (APF)</b></div><div>915 St. Elmo Avenue</div><div>Suite 200</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 866-APF-3635 (toll-free); 301-347-7166</div><div><b>Email:</b> porphyrus@porphyriafoundation.com</div><div><a href="https://www.porphyriafoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org</a></div></li><li class="half_rhythm"><div><b>European Porphyria Network</b></div><div><b>Email:</b> contact@porphyria.eu</div><div><a href="http://porphyria.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyria.eu</a></div></li><li class="half_rhythm"><div><b>Swedish Porphyria Patients' Association</b></div><div>Karolinska Universitetssjukhuset</div><div>Huddinge M 96</div><div>Stockholm Stockholms Lan SE-141 86</div><div>Sweden</div><div><b>Phone:</b> +46 8 711 56 09 </div><div><b>Email:</b> porfyrisjukdomar@gmail.com</div><div><a href="http://www.porfyri.se" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porfyri.se</a></div></li></ul></div><div id="porphyria-ct.Molecular_Genetics"><h2 id="_porphyria-ct_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="porphyria-ct.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Familial Porphyria Cutanea Tarda: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK143129/table/porphyria-ct.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-ct.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_porphyria-ct.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_porphyria-ct.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_porphyria-ct.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_porphyria-ct.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_porphyria-ct.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_porphyria-ct.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_porphyria-ct.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7389" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>UROD</i></a></td><td headers="hd_b_porphyria-ct.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7389" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p34<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_porphyria-ct.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P06132" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Uroporphyrinogen decarboxylase</a></td><td headers="hd_b_porphyria-ct.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/UROD" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UROD database</a></td><td headers="hd_b_porphyria-ct.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=UROD" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UROD</a></td><td headers="hd_b_porphyria-ct.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=UROD[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UROD</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="porphyria-ct.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="porphyria-ct.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Familial Porphyria Cutanea Tarda (<a href="/omim/176100,613521" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK143129/table/porphyria-ct.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-ct.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/176100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">176100</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PORPHYRIA CUTANEA TARDA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613521" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613521</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UROPORPHYRINOGEN DECARBOXYLASE; UROD</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The <i>UROD</i> transcript reference sequence <a href="/nuccore/NM_000374.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000374.4</a> has ten exons. See <a href="/books/NBK143129/#porphyria-ct.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants.</b> More than 100 different <i>UROD</i> pathogenic variants have been identified in individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> porphyria cutanea tarda (F-PCT). F-PCT-related <i>UROD</i> pathogenic variants include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> (the most common), <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; several small and large deletions; and small insertions [<a class="bk_pop" href="#porphyria-ct.REF.anderson.2001">Anderson et al 2001</a>].</p><p>Homozygosity for <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles is lethal [<a class="bk_pop" href="#porphyria-ct.REF.phillips.2007.5079">Phillips et al 2007</a>].</p><p>Two pathogenic variants, p.Arg193Pro and c.636+1G&#x0003e;C, account for 74% of pathogenic alleles in Norway. The p.Arg193Pro is a <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> in this population [<a class="bk_pop" href="#porphyria-ct.REF.aarsand.2009.795">Aarsand et al 2009</a>]. The p.Gly281Glu <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is common in Spain [<a class="bk_pop" href="#porphyria-ct.REF.g_mezabecia.2013.89">G&#x000f3;mez-Abecia et al 2013</a>].</p><div id="porphyria-ct.T.urod_pathogenic_variants" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>UROD</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK143129/table/porphyria-ct.T.urod_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__porphyria-ct.T.urod_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.578G&#x0003e;C</td><td headers="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg193Pro</td><td headers="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/115583676" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000374<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_000365.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000365<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.636+1G&#x0003e;C</td><td headers="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.842G&#x0003e;A</td><td headers="hd_h_porphyria-ct.T.urod_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly281Glu</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>UROD</i> encodes the enzyme uroporphyrinogen decarboxylase (UROD). The protein encoded by the reference transcript has 367 amino acids (<a href="/protein/NP_000365.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000365.3</a>) (see <a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=1URO" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">protein structure</a>).</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Hepatic uroporphyrinogen decarboxylase enzyme activity less than approximately 20% of normal results in disease. Persons with F-PCT are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that reduces UROD activity and immunoreactivity to approximately 50% of normal in all tissues. Persons with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> PCT are asymptomatic &#x02013; despite having a baseline decreased UROD activity &#x02013; until exposure to one or more susceptibility factors leads to increased oxidation and a subsequent further decrease of enzyme activity. Loss of enzyme activity results in accumulation of highly carboxylated porphyrins, which causes clinical features.</p></div><div id="porphyria-ct.References"><h2 id="_porphyria-ct_References_">References</h2><div id="porphyria-ct.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.aarsand.2009.795">Aarsand AK, Boman H, Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. <span><span class="ref-journal">Clin Chem. </span>2009;<span class="ref-vol">55</span>:795–803.</span> [<a href="/pubmed/19233912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19233912</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.anderson.1990.315">Anderson KE, Goeger DE, Carson RW, Lee SM, Stead RB. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. <span><span class="ref-journal">N Engl J Med. </span>1990;<span class="ref-vol">322</span>:315–7.</span> [<a href="/pubmed/2104958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2104958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.anderson.2001">Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaudet AL, Valle D, Sly WS, Childs B, Kinzler KW, Vogelstein B, eds. <em>The Metabolic and Molecular Bases of Inherited Disease</em>. 8 ed. New York, NY: McGraw-Hill; 2001:2961-2.</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.aziz_ibrahim.2004.574">Aziz Ibrahim A, Esen UI. Porphyria cutanea tarda in pregnancy: a case report. <span><span class="ref-journal">J Obstet Gynaecol. </span>2004;<span class="ref-vol">24</span>:574–5.</span> [<a href="/pubmed/15369945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15369945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.badenas.2009.346">Badenas C, To-Figueras J, Phillips JD, Warby CA, Mu&#x000f1;oz C, Herrero C. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. <span><span class="ref-journal">Clin Genet. </span>2009;<span class="ref-vol">75</span>:346–53.</span> [<a href="/pmc/articles/PMC3804340/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3804340</span></a>] [<a href="/pubmed/19419417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19419417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.barzilay.2001.195">Barzilay D, Orion E, Brenner S. Porphyria cutanea tarda triggered by a combination of three predisposing factors. <span><span class="ref-journal">Dermatology. </span>2001;<span class="ref-vol">203</span>:195–7.</span> [<a href="/pubmed/11586030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11586030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.bruce.1998.810">Bruce AJ, Ahmed I. Childhood-onset porphyria cutanea tarda: successful therapy with low-dose hydroxychloroquine (Plaquenil). <span><span class="ref-journal">J Am Acad Dermatol. </span>1998;<span class="ref-vol">38</span>:810–4.</span> [<a href="/pubmed/9591792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9591792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.cantatorefrancis.2010.529">Cantatore-Francis JL, Cohen-Pfeffer J, Balwani M, Kahn P, Lazarus HM, Desnick RJ, Schaffer JV. Hepatoerythropoietic porphyria misdiagnosed as child abuse: cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation. <span><span class="ref-journal">Arch Dermatol. </span>2010;<span class="ref-vol">146</span>:529–33.</span> [<a href="/pmc/articles/PMC3092549/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3092549</span></a>] [<a href="/pubmed/20479301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20479301</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.cassiman.2008.237">Cassiman D, Vannoote J, Roelandts R, Libbrecht L, Roskams T, Van den Oord J, Fevery J, Garmyn M, Nevens F. Porphyria cutanea tarda and liver disease: A retrospective analysis of 17 cases from a single centre and review of the literature. <span><span class="ref-journal">Acta Gastroenterol Belg. </span>2008;<span class="ref-vol">71</span>:237–42.</span> [<a href="/pubmed/18720935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18720935</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.christiansen.2005.227">Christiansen L, Br&#x000f8;ns-Poulsen J, H&#x000f8;rder M, Brock A, Petersen NE. Expression and characterization of six clinically relevant uroporphyrinogen decarboxylase gene mutations. <span><span class="ref-journal">Scand J Clin Lab Invest. </span>2005;<span class="ref-vol">65</span>:227–35.</span> [<a href="/pubmed/16095052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16095052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.dabski.1991.28">Dabski C, Beutner EH. Studies of laminin and type IV collagen in blisters of porphyria cutanea tarda and drug-induced pseudoporphyria. <span><span class="ref-journal">J Am Acad Dermatol. </span>1991;<span class="ref-vol">25</span>:28–32.</span> [<a href="/pubmed/1880250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1880250</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.desai.2012.41">Desai T, Bortman J, Al-Sibae R, Bonkovsky HL. The role of iron in hepatitis C infection. <span><span class="ref-journal">Curr Hepat Rep. </span>2012;<span class="ref-vol">11</span>:41–7.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.g_mezabecia.2013.89">G&#x000f3;mez-Abecia S, Mor&#x000e1;n-Jim&#x000e9;nez MJ, Ruiz-Casares E, Henriques-Gil N, Garc&#x000ed;a-Pastor I, Garrido-Astray MC, Enr&#x000ed;quez de Salamanca R, M&#x000e9;ndez M. Familial porphyria cutanea tarda in Spain: characterization of eight novel mutations in the UROD gene and haplotype analysis of the common p.G281E mutation. <span><span class="ref-journal">Gene. </span>2013;<span class="ref-vol">522</span>:89–95.</span> [<a href="/pubmed/23545314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23545314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.egger.2002.419">Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. <span><span class="ref-journal">Dig Dis Sci. </span>2002;<span class="ref-vol">47</span>:419–26.</span> [<a href="/pubmed/11855561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11855561</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.gisbert.2004.689">Gisbert JP, Garc&#x000ed;a-Buey L, Alonso A, Rubio S, Hern&#x000e1;ndez A, Pajares JM, Garc&#x000ed;a-D&#x000ed;ez A, Moreno-Otero R. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. <span><span class="ref-journal">Eur J Gastroenterol Hepatol. </span>2004;<span class="ref-vol">16</span>:689–92.</span> [<a href="/pubmed/15201583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15201583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.grossman.1979.277">Grossman ME, Bickers DR, Poh-Fitzpatrick MB, Deleo VA, Harber LC. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. <span><span class="ref-journal">Am J Med. </span>1979;<span class="ref-vol">67</span>:277–86.</span> [<a href="/pubmed/463934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 463934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.mehrany.2004.205">Mehrany K, Drage LA, Brandhagen DJ, Pittelkow MR. Association of porphyria cutanea tarda with hereditary hemochromatosis. <span><span class="ref-journal">J Am Acad Dermatol. </span>2004;<span class="ref-vol">51</span>:205–11.</span> [<a href="/pubmed/15280838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15280838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.mu_ozsantos.2011.486">Mu&#x000f1;oz-Santos C, Guilabert A, Moreno N, Gimenez M, Darwich E, To-Figueras J, Herrero C. The association between porphyria cutanea tarda and diabetes mellitus: analysis of a long-term follow-up cohort. <span><span class="ref-journal">Br J Dermatol. </span>2011;<span class="ref-vol">165</span>:486–91.</span> [<a href="/pubmed/21564073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21564073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.mu_ozsantos.2010.69">Mu&#x000f1;oz-Santos C, Guilabert A, Moreno N, To-Figueras J, Badenas C, Darwich E, Herrero C. Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients. <span><span class="ref-journal">Medicine (Baltimore). </span>2010;<span class="ref-vol">89</span>:69–74.</span> [<a href="/pubmed/20517178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20517178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.phillips.2007.5079">Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2007;<span class="ref-vol">104</span>:5079–84.</span> [<a href="/pmc/articles/PMC1820519/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1820519</span></a>] [<a href="/pubmed/17360334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17360334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.pobleteguti_rrez.2004.372">Poblete-Guti&#x000e9;rrez P, Mendez M, Wiederholt T, Merk HF, Fontanellas A, Wolff C, Frank J. The molecular basis of porphyria cutanea tarda in Chile: identification and functional characterization of mutations in the uroporphyrinogen decarboxylase gene. <span><span class="ref-journal">Exp Dermatol. </span>2004;<span class="ref-vol">13</span>:372–9.</span> [<a href="/pubmed/15186324" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15186324</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.ratnaike.1988.3">Ratnaike S, Blake D, Campbell D, Cowen P, Varigos G. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. <span><span class="ref-journal">Australas J Dermatol. </span>1988;<span class="ref-vol">29</span>:3–8.</span> [<a href="/pubmed/3250437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3250437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.rocchi.1999.861">Rocchi E, Casalgrandi G, Masini A, Giovannini F, Ceccarelli D, Ferrali M, Marchini S, Ventura E. Circulating pro- and antioxidant factors in iron and porphyrin metabolism disorders. <span><span class="ref-journal">Ital J Gastroenterol Hepatol. </span>1999;<span class="ref-vol">31</span>:861–7.</span> [<a href="/pubmed/10669994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10669994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.rocchi.1987.393">Rocchi E, Cassanelli M, Ventura E. High weekly intravenous doses of desferrioxamine in porphyria cutanea tarda. <span><span class="ref-journal">Br J Dermatol. </span>1987;<span class="ref-vol">117</span>:393–6.</span> [<a href="/pubmed/3676087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3676087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.rocchi.1986.36">Rocchi E, Gibertini P, Cassanelli M, Pietrangelo A, Borghi A, Ventura E. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. <span><span class="ref-journal">J Lab Clin Med. </span>1986;<span class="ref-vol">107</span>:36–42.</span> [<a href="/pubmed/3941293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3941293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.rossmannringdahl.2005.337">Rossmann-Ringdahl I, Olsson R. Porphyria cutanea tarda in a Swedish population: risk factors and complications. <span><span class="ref-journal">Acta Derm Venereol. </span>2005;<span class="ref-vol">85</span>:337–41.</span> [<a href="/pubmed/16191856" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16191856</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.ryan_caballes.2012.880">Ryan Caballes F, Sendi H, Bonkovsky HL. Hepatitis C, porphyria cutanea tarda and liver iron: an update. <span><span class="ref-journal">Liver Int. </span>2012;<span class="ref-vol">32</span>:880–93.</span> [<a href="/pmc/articles/PMC3418709/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3418709</span></a>] [<a href="/pubmed/22510500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22510500</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.shieh.2000.645">Shieh S, Cohen JL, Lim HW. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. <span><span class="ref-journal">J Am Acad Dermatol. </span>2000;<span class="ref-vol">42</span>:645–52.</span> [<a href="/pubmed/10727312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10727312</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.sinclair.1997.197">Sinclair PR, Gorman N, Shedlofsky SI, Honsinger CP, Sinclair JF, Karagas MR, Anderson KE. Ascorbic acid deficiency in porphyria cutanea tarda. <span><span class="ref-journal">J Lab Clin Med. </span>1997;<span class="ref-vol">130</span>:197–201.</span> [<a href="/pubmed/9280147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9280147</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.sixeldietrich.1985.13">Sixel-Dietrich F, Doss M. Hereditary uroporphyrinogen-decarboxylase deficiency predisposing porphyria cutanea tarda (chronic hepatic porphyria) in females after oral contraceptive medication. <span><span class="ref-journal">Arch Dermatol Res. </span>1985;<span class="ref-vol">278</span>:13–6.</span> [<a href="/pubmed/4096525" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4096525</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.st_lzel.2003.309">St&#x000f6;lzel U, Koestler E, Schuppan D, Richter M, Wollina U, Doss MO, Wittekind C, Tannapfel A. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. <span><span class="ref-journal">Arch Dermatol. </span>2003;<span class="ref-vol">139</span>:309–13.</span> [<a href="/pubmed/12622622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12622622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.toll_nes.2011.217">Toll&#x000e5;nes MC, Aarsand AK, Sandberg S. Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study. <span><span class="ref-journal">J Inherit Metab Dis. </span>2011;<span class="ref-vol">34</span>:217–23.</span> [<a href="/pmc/articles/PMC3026662/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3026662</span></a>] [<a href="/pubmed/20978938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20978938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="porphyria-ct.REF.wissel.1987.107">Wissel PS, Sordillo P, Anderson KE, Sassa S, Savillo RL, Kappas A. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome. <span><span class="ref-journal">Am J Hematol. </span>1987;<span class="ref-vol">25</span>:107–13.</span> [<a href="/pubmed/3578259" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3578259</span></a>]</div></li></ul></div></div><div id="porphyria-ct.Chapter_Notes"><h2 id="_porphyria-ct_Chapter_Notes_">Chapter Notes</h2><div id="porphyria-ct.Acknowledgments"><h3>Acknowledgments</h3><p>On behalf of the Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network; including Dr. Karl Anderson, University of Texas Medical Branch, Galveston, TX; Dr. Montgomery Bissell, University of California, San Francisco, CA; Dr. Herbert Bonkovsky, Carolinas Medical Center, Charlotte, NC; Dr. John Phillips, University of Utah School of Medicine, Salt Lake City, UT</p></div><div id="porphyria-ct.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>8 September 2016 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 August 2013 (me) Comprehensive update posted live; <i>GeneReview</i> divided into type II porphyria cutanea tarda and hepatoerythropoietic porphyria</div></li><li class="half_rhythm"><div>6 June 2013 (me) Review posted live</div></li><li class="half_rhythm"><div>26 April 2012 (hb) Original Submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK143129</span><span class="label">PMID: <a href="/pubmed/23741761" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">23741761</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/pnknd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/fa/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK143129&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK143129/?report=reader">PubReader</a></li><li><a href="/books/NBK143129/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK143129" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK143129" style="display:none" title="Cite this Page"><div class="bk_tt">Liu LU, Phillips J, Bonkovsky H; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Familial Porphyria Cutanea Tarda. 2013 Jun 6 [Updated 2016 Sep 8]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK143129/pdf/Bookshelf_NBK143129.pdf">PDF version of this page</a> (441K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#porphyria-ct.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#porphyria-ct.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#porphyria-ct.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#porphyria-ct.Genetically_Related_Allelic" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#porphyria-ct.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#porphyria-ct.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#porphyria-ct.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#porphyria-ct.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#porphyria-ct.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#porphyria-ct.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#porphyria-ct.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7389[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">UROD</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3077[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">HFE</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3034214" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3034214" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3034214" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3034214" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24175354" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hepatoerythropoietic Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hepatoerythropoietic Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Liu LU, Phillips J, Bonkovsky H, Porphyrias Consortium of the Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409300" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Singal AK, Anderson KE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301372" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Acute Intermittent Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Acute Intermittent Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Whatley SD, Badminton MN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30514647" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Porphyria cutanea tarda and hepatoerythropoietic porphyria: Identification of 19 novel uroporphyrinogen III decarboxylase mutations.</a><span class="source">[Mol Genet Metab. 2019]</span><div class="brieflinkpop offscreen_noflow">Porphyria cutanea tarda and hepatoerythropoietic porphyria: Identification of 19 novel uroporphyrinogen III decarboxylase mutations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Weiss Y, Chen B, Yasuda M, Nazarenko I, Anderson KE, Desnick RJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Genet Metab. 2019 Nov; 128(3):363-366. Epub 2018 Nov 28.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20955974" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Porphyria cutanea tarda--when skin meets liver.</a><span class="source">[Best Pract Res Clin Gastroente...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Porphyria cutanea tarda--when skin meets liver.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Frank J, Poblete-Gutiérrez P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Best Pract Res Clin Gastroenterol. 2010 Oct; 24(5):735-45. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=23741761" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=23741761" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0410c6dd21425a2597fcaa">Familial Porphyria Cutanea Tarda - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Familial Porphyria Cutanea Tarda - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:45:42-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C9E6FE03FBE0100000000081702F1&amp;ncbi_session=CE8C9E6FE0410C61_2071SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK143129%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK143129&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK143129/&amp;ncbi_pagename=Familial Porphyria Cutanea Tarda - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C9E6FE0410C61_2071SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>